Aug 12, 2021 4:15 pm EDT EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 11, 2021 4:15 pm EDT EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Aug 10, 2021 6:55 am EDT EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jul 26, 2021 4:15 pm EDT EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
Jun 14, 2021 6:55 am EDT EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study
May 12, 2021 4:15 pm EDT EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
Apr 1, 2021 6:55 am EDT EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
Mar 25, 2021 4:15 pm EDT EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update
Feb 1, 2021 6:55 am EST EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation